Apple (NASDAQ:AAPL): Pacific Crest believes that iPhone unit volumes will stay healthy through the launch of new devices later this year, and believes that cost savings will help keep iPhone gross margins stable, although it contends that iPad demand is trending below its expectations. The firm thinks the stock could reach the high end of its $430-$530 fair value range, although it keeps a Sector Perform rating on the shares.
Biogen (NASDAQ:BIIB): Citigroup has brought Biogen to Buy from Neutral, saying EMA’s reversal of its opinion on Sanofi’s (NYSE:SNY) Aubagio treatment is a big positive for the company. The firm has a $236 price target for shares.
Nike (NYSE:NKE): Stifel believes that Nike’s Q1 gross margin guidance is likely conservative, after the company reported better than expected Q4 results. The firm thinks the company’s China business could rebound sooner than it indicated, and keeps a Buy rating on the stock.
Goldman Sachs (NYSE:GS): JMP Securities has lowered its Q2 EPS estimate for Goldman to $2.72 from $3.13, mostly due to weaker than expected trading activity. The firm believes that the company’s trading and banking businesses remain largely range-bound with no sign of acceleration, and it reiterates a Market Perform rating on the stock.
Don’t Miss: Did This Apple Supplier Just Make the iWatch?